Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The University of Texas Health Science Center, Houston | OTHER |
| Loma Linda University | OTHER |
| Minnesota Oral & Facial Surgery | UNKNOWN |
| University of Alabama at Birmingham |
Not provided
Not provided
Not provided
The purpose of this study is to validate the ability of the STRATICYTEâ„¢ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.
The study objectives are to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OPMDs that progressed to OSCC | No dysplasia, mild, moderate, severe dysplasia, CIS |
| |
| OPMDs that did not progress to OSCC | No dysplasia, mild, moderate, severe dysplasia, CIS |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STRATICYTEâ„¢ Test | Other | Assessment for risk of progression to oral cancer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity and Specificity | Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy | 5 years |
| Survival analysis | Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTEâ„¢ classification of Low- and Elevated-Risk. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| AUC | Area under the receiver operator curve | 5 years |
| C-index (Harrell's) | From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The target population are patients presenting with an OPMD who have received a biopsy of their lesion. The study sample will be composed of patients with previously biopsied OPMDs from contracted clinics.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jody Filkowski, BSc, MSc, PhD | Contact | 1-825-305-0749 | Jody.Filkowski@medlior.com | |
| Jason TK Hwang, HBSc, MSc, PhD | Contact | 1-647-255-1370 | jhwang@proteocyte.com |
| Name | Affiliation | Role |
|---|---|---|
| Simon W Young, DDS, MD, PhD | UTHealthHouston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Alabama at Birmingham | Completed | Birmingham | Alabama | 35233 | United States | |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41054469 | Background | Hwang JTK, Dammling C, McCord C, McGuire T, Park EP, Filkowski J, Shaw E, McMullen S, Nwigwe A, Ekwaru JP, McGaw WT, Lung KE, Seikaly H, Renick B, Lin DM, Morlandt A, Pritzker KH, Darling MR. External Validation of Straticyte, a Quantitative Biomarker-Based Risk Assay in Predicting Oral Cancer. J Maxillofac Oral Surg. 2025 Oct;24(5):1351-1357. doi: 10.1007/s12663-024-02362-7. Epub 2024 Oct 29. | |
| 18339795 |
| Label | URL |
|---|---|
| Medlior Health Outcomes Research | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D007971 | Leukoplakia |
| D004919 | Erythroplasia |
| D004194 | Disease |
| D006965 | Hyperplasia |
| D053546 | Keratoderma, Palmoplantar, Epidermolytic |
| ID | Term |
|---|---|
| D009057 | Stomatognathic Diseases |
| D011230 | Precancerous Conditions |
| D009369 | Neoplasms |
| D020763 | Pathological Conditions, Anatomical |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
FFPE specimens immunohistochemically stained with S100A7
| 5 years |
| Loma Linda University |
| Completed |
| Loma Linda |
| California |
| 92350 |
| United States |
| Minnesota Oral and Facial Surgery | Withdrawn | Minneapolis | Minnesota | 55415 | United States |
| MD Anderson Cancer Cetner | Recruiting | Houston | Texas | 44907 | United States |
|
| UTHealth Houston School of Dentistry | Completed | Houston | Texas | 77054 | United States |
| Background |
| Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008 Jun;7(6):1162-73. doi: 10.1074/mcp.M700500-MCP200. Epub 2008 Mar 13. |
| 19072117 | Background | Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j. |
| 20689826 | Background | Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939. |
| 24122701 | Background | Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8. |
| 28110942 | Background | Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22. |
| Oral Cancer Foundation | View source |
| Proteocyte Diagnostics Inc. | View source |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D015776 | Keratoderma, Palmoplantar, Diffuse |
| D007645 | Keratoderma, Palmoplantar |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007642 | Keratosis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |